AstraZeneca's (AZN) Imfinzi Improves Survival in SCLC Study

AstraZeneca (AZN) announced positive data from the phase III ADRIATIC study, which evaluated its blockbuster cancer drug, Imfinzi (durvalumab), for treating patients with limited-stage small cell lung cancer (LS-SCLC), an aggressive form of lung cancer.The dual primary endpoints of this global phase III study are overall survival (OS) and progression-free survival (PFS).Data from the study showed that treatment with Imfinzi led to statistically significant and clinically meaningful improvement in the OS and ...